Te­va suf­fers set­back on in-house asth­ma pro­gram as a PhII study is halt­ed ear­ly due to fu­til­i­ty

Al­though Te­va large­ly makes its mon­ey these days through gener­ic drug sales, the com­pa­ny con­tin­ues to de­vel­op a suite of asth­ma med­i­cines and in­halers for …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER